Precision BioSciences offers high-risk, high-reward potential, trading below cash with key HBV and DMD data catalysts ...

By broadening definition of success to include sustained low-level HBsAg with suppressed HBV DNA, we can recognize clinically ...

Medically reviewed by Steffini Stalos, DOKey TakeawaysHepatitis B can be treated and prevented, but it cannot be ...

-- VRON-0200 was safe and well tolerated, with no serious treatment-related adverse events, treatment discontinuations, or treatment-related clinical laboratory abnormalities reported -- In the ...

"Our findings underscore the critical role of epigenetic mechanisms in HBV pathogenesis. By targeting these pathways, we can develop therapies that not only suppress viral replication but also offer a ...

Hepatitis B virus (HBV) infects more than 250 million people worldwide and can lead to chronic liver disease and liver cancer ...

Please provide your email address to receive an email when new articles are posted on . The cumulative probability of functional cure was 14.53% at a mean age of 25.75 years. The annual cure rate was ...

SAN FRANCISCO, Dec. 12, 2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company developing oligonucleotide-based ...

Virion Therapeutics Announces Upcoming Clinical Presentation Highlighting VRON-0200 Study Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2025 Virion Therapeutics, LLC, a ...

ST. LOUIS – Hepatitis B virus, a killer of more than one million people each year, is a notoriously wily virus, often lingering and resurfacing even after treatment. But, thanks to a new class of ...

Particularities of the HBV cycle that favour the development of chronic infection (centre), the clinical challenges stemming from these biological characteristics (top) and the opportunities currently ...